Predict your next investment

HEALTHCARE | Drug Development
ribotargets.com

See what CB Insights has to offer

Founded Year

1997

Stage

Merger | Acquired

Total Raised

$67.61M

About RiboTargets

Developer of an innovative drug design and development engine focused on the use of structure-based design to improve the drug discovery process. The company uses its structure-based design approach on targets that have been validated to progress compounds through lead optimisation and clinical development. The company's focus is on two therapeutic areas, anti-bacterials and anti-cancers, which are complementary in managing risk within a research and development portfolio. The drug design and development engine utilises in silico screening together with detailed ligand and fragment based approaches to generate hit compounds. Assay, structural and computational approaches are used to progress high quality, validated lead candidates to pre-clinical development. This "structure to development candidate" platform enhances the drug-like features of leads, improving their quality and potential to succeed.

RiboTargets Headquarter Location

Granta Park Abington

Cambridge, CB1 6GB,

United Kingdom

44 122 389 5555

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.